Wang, Zhuoran; Zhao, Yue; Zhang, Shuai; Chen, Xuehui; Sun, Guoming; Zhang, Baoli; Jiang, Bing; Yang, Yili; Yan, Xiyun; Fan, Kelong published the artcile< Re-engineering the inner surface of ferritin nanocage enables dual drug payloads for synergistic tumor therapy>, Quality Control of 112-63-0, the main research area is ferritin nanocage drug synergistic tumor therapy liver cancer; dual drug payloads; hydrophobic drugs loading; inner surface engineering; re-design of ferritin nanocage; synergistic tumor therapy.
With the advantages of tumor-targeting, pH-responsive drug releasing, and biocompatibility, ferritin nanocage emerges as a promising drug carrier. However, its wide applications were significantly hindered by the low loading efficiency of hydrophobic drugs. Herein, we redesigned the inner surface of ferritin drug carrier (ins-FDC) by fusing the C- terminus of human H ferritin (HFn) subunit with optimized hydrophobic peptides. Hydrophobic and hydrophilic drugs were encapsulated into the ins-FDC through the urea-dependent disassembly/reassembly strategy and the natural drug entry channel of the protein nanocage. The morphol. and drug loading/releasing abilities of the drug-loaded nanocarrier were then examined Its tumor targeting character, system toxicity, application in synergistic therapy, and anti-tumor action were further investigated. After optimization, 39 hydrophobic Camptothecin and 150 hydrophilic Epirubicin were encapsulated onto one ins-FDC nanocage. The ins-FDC nanocage exhibited programed drug release pattern and increased the stability and biocompatibility of the loaded drugs. Furthermore, the ins-FDC possesses tumor targeting property due to the intrinsic CD71-binding ability of HFn. The loaded drugs may penetrate the brain blood barrier and accumulate in tumors in vivo more efficiently. As a result, the drugs loaded on ins-FDC showed reduced side effects and significantly enhanced efficacy against glioma, metastatic liver cancer, and chemo-resistant breast tumors. The ins-FDC nanocarrier offers a promising novel means for the delivery of hydrophobic compounds in cancer treatments, especially for the combination therapies that use both hydrophobic and hydrophilic chemotherapeutics.
Theranostics published new progress about Antitumor agents. 112-63-0 belongs to class esters-buliding-blocks, and the molecular formula is C19H34O2, Quality Control of 112-63-0.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics